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KEY POINTS 
1. Causes of short gut syndrome involve both surgical 
causes (e.g., volvulus, necrotizing enterocolitis, 
mesenteric thrombosis) or functional causes such 
as motility disorders (e.g., intestinal pseudo-
obstruction) and absorptive insufficiencies such as 
microvillous inclusion disease. 
2. Indications for intestinal transplantation approved 
by Medicare in 2000 include (1) evidence of liver 
dysfunction or failure; (2) loss of major venous 
access; (3) frequent central line-related sepsis; (4) 
recurrent episodes of severe dehydration despite 
intravenous fluid management. 
3. Recipient operations should be tailored to the 
specific indications of each patient and include 
isolated intestinal transplantation, combined liver-
intestinal transplantation, and multivisceral trans-
plantation, including the stomach. 
4. Immunosuppression for intestinal transplantation 
is based on tacrolimus and steroids. Current 
modifications in intestinal transplantation include 
pretreatment of the recipient with antilymphocyte 
antibody such as antithymocyte antibody to allow 
for the elimination of maintenance steroid use 
postoperatively. 
5. Sepsis after intestinal transplantation should prompt 
a rapid examination for technical reasons (e.g., 
intra-abdominal abscess, anastomotic dehiscence), 
immunologic events (rejection may lead to bacterial 
translocation), or Epstein Barr virus-mediated 
viremia or post-transplant lymphoproliferative 
disease. 
The evolution of intestinal transplantation has distantly par-
alleled that of kidney and liver transplantation. Although the 
introduction of cyclosporin A made other organ transplants a 
clinical reality, success with intestinal transplantation 
remained almost nonexistent due to a high incidence of graft 
loss from rejection, infection, and technical complications.! 
The experimental studies on intestinal transplantation 
reported by Lillehei and colleagues in 1959 as an isolated organ 
graft in dogs,2 and subsequently by Starzl and colleagues with 
the multivisceral graft in dogs (liver, stomach, pancreatico-
duodenal complex, small and large intestine)3 supported a 
unidirectional paradigm of transplantation and immunology 
similar to that found after bone marrow transplantation.4 
These experiments predicted that graft-versus-host disease 
would be precipitated by immunocytes in lymphoid cell-rich 
intestinal allografts differing from the recipient across a 
major histocompatibility complex barrier.5 
Numerous attempts at clinical intestinal transplantation 
performed after 1964 under azathioprine/steroid and 
subsequently cyclosporine immunosuppression were largely 
unsuccessful. In 1987, a 3-year-old girl received a multivis-
ceral abdominal graft that included the stomach, duodenum, 
pancreas, small bowel, colon, and liver; she survived for 
6 months with good intestinal graft function.6 A modified 
application of this operation was the transplantation of a 
"cluster" of organs in 1989.7 The allograft consisted of the 
liver and the pancreaticoduodenal complex (Fig. 236-1). 
Viability of varying lengths of intestine with these clusters 
was proven, as was evidence of regeneration after severe 
rejection-induced injury. The inclusion of the liver in this 
type of graft was believed to protect the other transplanted 
organs from the same donor against rejection.8,9 A recipient 
of a liver and small bowel graft treated by Grant and associates 
survived for more than 1 year. 10 Until 1990, there were only 
two survivors of isolated cadaveric intestinal grafts. 11,!2 
The new immunosuppress'ant, tacrolimus (FK506, 
Prograf), permitted successful transplantation of human 
intestinal grafts (alone or as part of a multivisceral graft).13,14 
Successful intestinal transplantation then led to appreciation 
of the two-way paradigm of transplantation immunology!5; 
it was postulated that two cell populations (one of recipient 
and the other of donor origin) reciprocally modulate immune 
responsiveness (host-versus-graft and graft-versus-host), 
including the induction of mutual nonreactivity with conse-
quent organ allograft acceptance.16 
INDICATIONS 
Causes of loss of intestinal function may be acute (e.g., 
necrotizing enterocolitis, volvulus, mesenteric thrombosis) 
or chronic (e.g., Crohn's disease, radiation enteritis). Diseases 
associated with loss of intestinal function also can be divided 
into surgical (short gut) and nonsurgical causes. Patients 
with surgical causes generally suffer from loss of bowel 
length after resections for atresia, infarction (e.g., due to 
volvulus, vascular catastrophes, necrotizing enterocolitis), or 
strictures and fistulas as with Crohn's disease. With non-
surgical causes of intestinal failure, the anatomic length 
and gross morphology of the intestine may be normal. 
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FIGURE 236-1. Cluster allograft (shaded portion), including the liver, 
pancreas, and duodenal segment of small intestine. (From Starzl TE, 
Todo S, Tzakis A, et al: Abdominal organ cluster transplantation for the 
treatment of upper abdominal malignancies. Ann Surg 1989;210:374-386.) 
Nonsurgical causes of intestinal failure include motility 
disorders (e.g., intestinal pseudo-obstruction, Hirschsprung's 
disease), absorptive problems (e.g., microvillus inclusion dis-
ease), polyposis syndromes, and "incarcerating" desmoid 
tumors. Table 236-1 lists the indications for transplantation 
in the case experience at the University of Pittsburgh. 
Total parenteral nutrition (TPN) is the standard of care 
for patients who are unable to maintain a normal nutritional 
state by use of the gastrointestinal tract alone (intestinal 
failure)Y Transplantation of the intestine either alone or 
accompanied by other intra-abdominal organs (liver, stomach, 
pancreas) may be beneficial in patients who fail this therapy. 
The stability and duration of TPN support is variable, and 
TABLE 236-1. INDICATIONS FOR COMPOSITE AND 
ISOLATED INTESTINAL TRANSPLANTATION AT THE 
UNIVERSITY OF PITTSBURGH AND CHILDREN'S 
HOSPITAL OF PITTSBURGH 
Pediatric Patients 
Volvulus 
Gastroschisis 
Necrotizing enterocolitis 
Intestinal atresia 
Pseudo-obstruction 
Microvillus inclusion disease 
Intestinal polyposis 
Hirschsprung's disease 
Trauma 
Adult Patients 
Trauma 
Superior mesenteric artery 
thrombosis 
Crohn's disease 
Desmoid tumor 
Volvulus 
Familial polyposis 
Gastrinoma 
Budd-Chiari disease 
Intestinal adhesions 
Pseudo-obstruction 
Inflammatory bowel disease 
Radiation enteritis 
failure of TPN can be manifested by complications such as 
infection, metabolic disorders, difficulty with vascular access 
(from extensive venous thrombosis), and liver cirrhosis with 
end-stage liver disease. 
The decision regarding allograft composition focuses on 
the integrity of the remaining gut and other abdominal 
organs, both functionally and anatomically. Guidelines used 
in substantiating the need for concomitant liver replacement 
in these intestinal transplantation candidates are biochemi-
cal dysfunction (hyperbilirubinemia, transaminase abnor-
malities, hypoalbuminemia, and coagulopathy), pathologic 
processes (fibrosis or cirrhosis on liver biopsy), and the 
clinical presence of portal hypertension as manifested 
by hepatosplenomegaly, ascites, or esophageal varices and 
portal hypertensive gastroenteropathy. Patients deficient in 
protein S, protein C, and antithrombin III (liver-derived 
anticoagulation proteins) may be candidates for a combined 
liver-small intestine allograft in the absence of clinical liver 
disease. IS Recipients lacking these substances develop diffuse 
thromboses within the splanchnic system and undergo 
transplantation for mesenteric venous hypertension rather 
than for intestinal failure. Patients with motility disorders or 
neoplasms that involve extensive lengths of the gastrointestinal 
tract are also candidates for replacement of this entire system 
(see Table 236-1). 
In October 2000, the Center for Medicare and Medicaid 
Services approved intestinal, combined liver-intestine, and 
multivisceral transplantation as a standard of care for patients 
with irreversible intestinal failure who could no longer be 
maintained with total parenteral nutrition. Based on the 
available data, the approved indications for intestinal trans-
plantation included (1) impending liver failure, as manifested 
by elevated circulating levels ofliver enzymes, clinical findings 
(splenomegaly, varices, coagulopathy), history of stomal 
bleeding, OF hepatic cirrhosis on biopsy; (2) loss of major 
venous access defined as more than two thromboses in the 
great vessels (subclavian, jugular, and femoral veins); (3) fre-
quent central line-related sepsis consisting of more than two 
episodes of systemic sepsis per year, or one episode of line-
related fungemia associated with septic shock or acute respi-
ratory distress syndrome; (4) recurrent episodes of severe 
dehydration despite intravenous fluid management. 19,20 
ABDOMINAL VISCERAL PROCUREMENT 
The safe procurement of multiple visceral organs, either en 
bloc or as separate components, hinges on a few fundamental 
precepts. Conceptually, the focus is to isolate and cool the 
organs, thus preserving their vascular and parenchymal 
anatomy and function. Multivisceral en bloc retrieval, 
including the stomach, duodenum, pancreas, liver, and small 
intestine, is the parent operation, and the assembled compo-
nents have been likened by Starzl and colleagues to a large 
clump of individual grapes from the whole. 21 An appreciation 
of the fundamental strategy of multivisceral organ retrieval 
leads to an understanding of the lesser variant operations 22-
that is, procurement of the liver, small intestine, and the liver 
and small intestine together. 
~ob~C=f~mf~b~k~q~l~m~b~oA~r~f=l~k=p _______________ _ 
Most patients who need intestinal or multiorgan repla~e­
ments have had multiple forays into the abdominal cavity 
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FIGURE 236-2. (A) Arterialization and potential venous drainage options of the isolated small intestine allograft. (8) Illustration of an isolated small 
bowel graft; the distal ileal chimney allows easy access to bowel mucosa. Ao, aorta; IVC, inferior vena cava; PV, portal vein; SMV, superior mesenteric 
vein; SV, splenic vein. (From Reyes J, Bueno J, Kocoshis 5, et al: Current status of intestinal transplantation in children. J Pediatric Surg 1998;33:243-254.) 
for intestinal resections, lengthening procedures, and treat-
ment of complications. This results in volume contraction of 
the abdominal cavity and severe adhesions. Consequently, 
the organs of the donor usually need to be smaller than those 
of the recipient to ensure proper abdominal closure. 
In an effort to maximize organ utilization and improve 
abdominal closure in children undergoing intestinal trans-
plantation, intestinal reduction with or without liver reduc-
tion has been used. For example, between July 2002 and 
September 2003, 31 children received consecutive intestinal 
transplants consisting of 14 isolated intestinal transplants, 
11 liver/intestinal transplants, 4 multivisceral transplants, 
and 2 modified multivisceral transplants without liver. 
Reduction of the liver and intestine has been carried out in 
17 of 31 cases (55%). A mean length of 1.3 meters of bowel 
has been reduced in these children, leaving a mean of 
2.2 meters (range: 1.1 to 3 meters). Based on these initial 
results, a donor weight to recipient weight ratio of up to 4:1 
has been a practical guideline to use in selection of donors 
larger than recipients. 
Previous operations may complicate the removal of the 
recipient's organs, especially if cirrhosis, portal hypertension, 
or inferior vena caval thromboses are present. All of these 
conditions can be sequelae of the original disease or of prior 
operations. The recipient operation consists of removal of 
the failed organs with exposure of the vascular anatomy and, 
finally, allograft implantation. Following is a brief description 
of the salient features of the recipient operations. 
\ ISOLATED SMALL BOWEL 
In cases of surgical short gut, the proximal and distal rem-
nants of the intestine are identified; when there is functional 
~isease or neoplasm, the recipient's diseased small intestine 
IS removed. The superior mesenteric artery of the donor 
bowel is sewn to the infrarenal aorta, and the donor superior 
mesenteric vein is anastomosed to the recipient portal vein, 
superior mesenteric vein, splenic vein, or inferior vena cava 
(Fig. 236-2A). The anastomosis can be facilitated by the use 
of an interposition venous graft. Reperfusion of the intestinal 
graft is effected after the vascular anastomoses. Intestinal 
continuity is completed with proximal and distal anasto-
moses, and access to the ileum for endoscopic examination is 
provided by a temporary chimney ileostomy (Fig. 236-2B).23 
Cold ischemia time refers to the time between procure-
ment and implantation of the allograft and should be less 
than 10 hours. Warm ischemic time for the allograft (sewing-in 
time) is about 30 minutes and is also a determinant of 
preservation injury to the intestine. In an attempt to reduce 
graft dysmotility, a segment of large intestine was included 
in 32 allografts. This practice was abandoned after 1994. 
LIVER-SMALL BOWEL 
Liver and small intestine are removed in these patients, but 
the remainder of the foregut (stomach, duodenum, pancreas) 
is retained. When possible, the liver is removed with the 
retrohepatic vena cava preserved in situ ("piggyback").24 After 
the enterectomy, the composite allograft is implanted 
by anastomosing the suprahepatic vena cava of the donor 
(including the hepatic veins) end-to-side to the recipient's 
vena cava. The donor infrahepatic vena cava can then be li-
gated (Fig. 236-3A). The double arterial stem of the celiac and 
superior mesenteric arteries (using the Carrel patch tech-
nique) are connected to the infrarenal aorta (using an aortic 
conduit or iliac artery homograft), followed by graft reper-
fusion. Since the axial stem of the portal vein between the 
donor organs is removed intact, all that is required for the 
completion of portal flow is attachment of the portal vein of 
the remnant foregut in the recipient to the intact portal stem 
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FIGURE 236-3. (A) Modification of the liver/small intestinal allograft. (8) Combined liver-small intestinal allograft. Systemic portacaval shunt, or 
recipient portal vein to donor portal vein shunt (inset) allows venous outflow of retained pancreas and stomach from recipient. (e) Composite liver 
and intestine graft with preservation of the duodenum in continuity with the graft jejunum and hepatic biliary system. The allograft pancreas is 
transected to the right of the portal vein. (0) In situ split liver graft, maintaining the left lateral segment in continuity with the hepatic hilus and 
duodenum, with transection of allograft pancreas. (8, from Reyes J, Bueno J, Kocoshis S, et al: Current status of intestinal transplantation in children) 
Pediatric Surg 1998;33:243-254; C, from Abu-Elmagd K, Reyes J, Todo S, et al: Clinical intestinal transplantation: New perspectives and immunologic 
considerations. J Am Coli Surg 1998;186:512-527; 0, from Reyes J, Fishbein T, Bueno J, et al: Reduced sized orthotopic composite liver-Intestinal 
allograft: Rationale and in situ split technique in an initial experience. Transplantation 1998;66:489-492.) 
of the donor. This may not be possible, however, because 
of a size discrepancy or difficult anatomic relationships 
between donor and recipient portal veins. In this case, a per-
manent portacaval shunt is performed (Fig. 236-3B). The 
intestinal anastomoses are then completed with a proximal 
jejunojejunostomy, ileocolostomy, a temporary distal 
ileostomy, and a Roux-en-Y biliary anastomosis. To avoid a 
biliary anastomosis (with its potential for complications), a 
modification of the original "cluster" allograft, as depicted in 
Figure 236-1, has been applied to the liver-small bowel 
allografts. 25 In the modification, the allograft duodenum 
remains in continuity with the allograft biliary system and 
varying lengths of allograft jejunum/ileum (Fig. 236-3C). In 
one such graft, a reduced segment of allograft liver (the le~ 
lateral segment) was successfully used after an in situ split 
was performed to overcome a donor-recipient size mismatch 
in a critically ill pediatric recipient (Fig. 236-3Dl. 
MULTIVISCERAL TRANSPLANTATION 
After abdominal e~ent~ration and exposure of ~he retrope:~ 
toneal aorta and mfenor vena cava, the multtvlsceral gr 
(Fig. 236-4A) is connected by its vascular attachrnen~sK 
First, the suprahepatic attachment is completed, then t e 
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FIGURE 236-4. Diagrams of 
multivisceral donor organs: complete 
multivisceral (A), modified multivisceral 
(8). (From Reyes J, Bueno J, Kocoshis S, 
et al: Current status of intestinal 
transplantation in children.J Pediatr 
Surg 1998;33:243-254.) 
A 
infrahepatic vena caval connections (or "piggyback" to the 
skeletonized recipient vena cava) are performed. Finally, 
the arterioaortic anastomosis (using an aortic interposition 
homograft) is completed. The recipient's portal vein and its 
inflow organs (gastrointestinal tract, pancreas, and liver) are 
removed with the enterectomy. The donor portal vein 
retains its continuity via the liver in the procurement of the 
allograft; thus, no portal vein anastomosis is required in this 
procedure. Patients with a normal native liver can receive a 
modified multivisceral procedure that excludes the allograft 
liver as part of the composite of organs. In this modification, 
portal venous return is directed into the recipient's portal 
vein (Fig. 236-4B). 
Restoration of intestinal continuity requires an esophago-
gastric anastomosis and a colo enteric anastomosis with the 
distal ileum allograft. Initially, the patient also receives an 
ileostomy. Takedown of the ileostomy can be performed 
after several months, when oral nutrition is consistently 
adequate, a stable immunosuppressant regimen has been 
achieved, and there is no further need for frequent endoscopic 
surveillance. 
!!!'!MUNOSUPPRESSION 
Traditionally, immunosuppression for intestinal transplanta-
tion has been based on tacrolimus and corticosteroids. Over 
time, however, the immunosuppressive regimen has evolved. 
From 1990 to 1995, the regimen used tacrolimus and corti-
Costeroids for induction and maintenance. Induction therapy 
with cyclophosphamide was used from 1995 through 1997. 
Daclizumab was used for induction from 1998 through 
2001. Preconditioning with Thymoglobulin during induction 
therapy and tacrolimus monotherapy (without steroids) after 
transplantation have been in use since 2001 (Table 236-2). 
The therapeutic principles of the current immunosuppression 
regimen are pretreatment of the recipient with a lymphocyte-
depleting agent to precondition the recipient, and then use 
B 
of the lowest possible amount of post-transplant immuno-
suppression to prevent frequent rejection episodes yet 
allow for the tolerogenic effect of the preconditioning to 
OCCUr.26 
In this management strategy, Thymoglobulin is given as 
an initial one-time dose of 5 to 10 mg/kg intravenously in 
adults or as 5 to 10 mg/kg in divided doses of 3 mg/kg 
pre-perfusion and 2 mg/kg post-perfusion in children. 
Subsequent to preconditioning, administration of tacrolimus 
is begun, using the enteral route. The target steady-state 
whole blood level of tacrolimus is between 15 and 20 ng/mL. 
Using the preconditioning regimen as outlined above 
has allowed the elimination of routine steroid use. 
Methylprednisolone is given as a bolus at perfusion and 
as premedication for the lymphocyte-depleting agent, but 
this drug is not used routinely. The dose is 1 g for adults and 
10 mg/kg for children. The goal of tacrolimus monotherapy 
has been achieved without an increase in rejection rates and 
with the resulting ability to achieve spaced dosing of 
tacrolimus to once a day, or even every other day. 
Prostaglandin EJ (Prostin) is administered at 0.003 to 
0.009 ~g/kg/min for the first 5 postoperative days. This drug is 
given for its beneficial effects on renal perfusion as well as its 
TABLE 236-2. INTESTINAL TRANSPLANTATION: 
IMMUNOSUPPRESSION BY ERA 
Years 
1990-1995 
1995-1997 
1997-1998 
1998-2001 
2002-2003 
TOTAL 
Drug CaRe~n 
Tacrolimus/steroids 70 
Tacrolimus/steroids Icyclophosphamide 24 
Tacrolimus/steroids 13 
Tacrolimus/steroids Idaclizumab 62 
Thymoglobulin preconditioning protocol 81 
250 
Pre 2002 Base-line Immunosuppression = tacrolimus + prednisone + 
azathioprine (n = 16), mycophenolate mofetil (n = 2), or sirolimus (n = 16) 
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prevention of microvascular thrombosis, a key patho-
physiologic event in acute cellular rejection and procure-
ment injury. Rejection is treated with optimization of 
tacrolimus levels, supplemental corticosteroids, and, if 
necessary,OKT3. 
POSTOPERATIVE CARE 
Recipients of multivisceral, liver-small bowel, or cluster 
grafts commonly suffer from severe liver failure. Therefore, 
the care with respect to pulmonary function, infection sur-
veillance, and liver graft function is similar to that provided 
for routine liver transplant recipients. Recipients of isolated 
small bowel transplants who have stable liver function have 
a lesser preoperative medical acuity. 
VENTILATORY MANAGEMENT 
Extubation often can be accomplished within 48 hours of 
transplantation. Unusual circumstances, such as graft 
malfunction, sepsis, inability to close the abdominal wall, or 
severe preoperative hepatic failure, may prevent early extu-
bation. Since the operation may be long (8 to 18 hours) and 
the patients are often in a weakened nutritional state pre-
operatively, a careful assessment of weaning parameters is 
required. Incisional pain, ascites, and pleural effusions may 
compromise ventilation and the ability to cough. Other fac-
tors that can contribute to respiratory dysfunction include 
muscle wasting and malnutrition, partial or complete paral-
ysis of the right hemidiaphragm,27 and increased intra-
abdominal volume with compression of the thoracic cavity 
due to a discrepancy between the size of the donor and the 
recipient. These patients often require low doses of intra-
venous narcotics, repeated thoracentesis and paracentesis, 
and supplemental extensive respiratory therapy if they are to 
avoid the need for reintubation. Patients may require tra-
cheostomy, because of the need for prolonged ventilatory 
support, although this is unusual in children. Rarely, severe 
rejection of an isolated small intestine allograft with sys-
temic venous drainage into the inferior vena cava is heralded 
by respiratory insufficiency and a clinical picture consistent 
with acute respiratory distress syndrome. 
RENAL FUNCTION 
Most intestinal transplant candidates have some degree of 
renal dysfunction due to multiple episodes of infection, the 
toxic effects of antibiotics, and hepatic dysfunction. Early 
after transplantation, there is significant accumulation of 
interstitial fluid into the graft, lungs, and peripheral tissues; 
this accumulation peaks at 48 to 72 hours. Extensive volume 
shifts into the transplanted bowel (related to preservation 
injury) and marked ascites production (related to mesenteric 
lymphatic leakage) lead to intravascular volume depletion 
that can exacerbate the nephrotoxicity of tacrolimus and 
certain antibiotics. Continuous central venous pressure 
measurement, often for weeks after transplantation, provides 
important information for maximizing graft perfusion and 
preserving the integrity of the kidneys. Two children have 
had inclusion of an allograft kidney with their primary 
intestine transplant, and one long-term pediatric survivor 
required sequential kidney transplantation. 
INFECTION CONTROL 
Recipients of isolated or composite small bowel grafts 
receive prophylactic, broad-spectrum intravenous antibiotics. 
Any history of recent nosocomial infections before trans_ 
plantation should be addressed with the administration of 
appropriate specific antibiotics. Colonizing organisms grOWing 
from enterocutaneous fistulous tracts should be treated 
perioperatively. 
All recipients are given a pre- and postoperative "cocktail" 
of oral nonabsorbable antibiotics every 6 hours for 2 weeks· 
the mixture includes amphotericin B, gentamicin, and 
polymyxin E and is intended to achieve selective bowel 
decontamination.28 Surveillance stool cultures are performed 
weekly. When organisms grow in quantitative cultures to 
greater than 108 colony-forming units/mL in the presence of 
signs of systemic sepsis or ongoing acute cellular rejection of 
the allograft, specifically directed intravenous antibiotics are 
added to the regimen to treat the presumed translocating 
organisms. Evidence of translocation most commonly 
occurs during episodes of acute rejection, when the mucosal 
barrier of the allograft has been immunologically damaged; 
however, it also can be seen with enteritis associated with 
Epstein-Barr virus infection.29 
The antiviral prophylactic strategy has evolved during 
the past several years. The currently recommended regimen 
includes a 2-week course of intravenous ganciclovir with 
concomitant administration of cytomegalovirus-specific 
hyperimmune globulin (Cytogam).30 The dose for ganci-
clovir is 5 mg/kg twice daily i.v. The dose for Cytogam is 
150 mg/kg i. v. in donor CMV ( +) to recipient CMV (-) mis-
match 2, 4, 6, and 8 weeks after transplant and 100 mg/kg! dose 
i.v. at 12 and 16 weeks after transplant. Oral administration 
of trimethoprim-sulfamethoxazole (80 mg p.o. three times 
weekly) is used for the lifetime of the patient as prophylaxis 
against Pneumocystis carinii pneumonia. 
NUTRITIONAL SUPPORT 
Full nutritional support is initially provided via standard 
total parenteral nutrition. This is tapered gradually as oral or 
enteral feedings (via gastric or jejunal tube) are advanced. 
Tube feedings are initiated with isotonic formulas tailored to 
meet specific patient requirements. Most patients do not vol-
untarily eat adequate amounts early after the operation. 
Resistance to resumption of oral feedings is particularly 
notable in pediatric recipients.3! Therefore, enteral supple-
mentation is required when the intestinal tract becomes 
functional. This management must be individualized, since 
the simplicity of an uneventful post-transplant cour~e 
may suddenly change with any surgical or immunologIC 
complication. 
ASSESSMENT OF GRAFT STATUS 
A judgment of the anatomic and functional integrity of the 
graft begins in the operating room. The normal intestine IS 
pink and nonedematous and occasionally demonstra~s 
contractions. Alterations from this appearance can e 
observed in the operating room and in the ileal stoma 
postoperatively. 
Surveillance for intestinal graft rejection focuS,es of 
clinical evaluation and gross morphologic examination 0 
t 
, 
the stoma and the distal ileum. Frequent routine entero-
scopic surveillance has been shown to be the most reliable 
tool for the early diagnosis of intestinal rejection.32 
Endoscopic evaluations are performed routinely twice a 
week through the allograft ileostomy; upper endoscopy is 
performed when clinical changes are not elucidated by distal 
allograft evaluation. Grossly, the bowel reacts to insults in 
nonspecific ways with edema, cyanosis, congestion, and 
increased stomal output; these alterations should signal a 
broad differential diagnosis that includes preservation 
injury, systemic sepsis, rejection, and enteritis. 
The stomal output is assessed for volume, consistency, 
and the presence of reducing substances, which can be seen in 
the event of rejection, bacterial overgrowth, or malabsorption. 
Typically, within the first week of implantation, stomal 
output is 1 to 2 Llday (for adults) or 40 to 60 mLlkg/day (for 
children) of clear, watery effluent. If these volumes are 
exceeded and no significant pathology is present, paregoric, 
loperamide, pectin, somatostatin, or oral antibiotics can be 
used singly or in combination to control the diarrhea. The 
presence of blood in the stool is always an ominous sign and 
indicates rejection until proven otherwise. 
Serum tests are important in assessing injury to the liver 
(bilirubin concentration, aspartate aminotransferase concen-
tration, and alanine aminotransferase concentration), but no 
such tests exist for intestinal grafts. Serum markers for nutri-
tional adequacy and anabolic status (circulating levels of 
transferrin, albumin, and retinoic acid) are of limited value, 
whereas specific tests of the absorptive ability of the graft are 
good measures of overall function. Assessment of small 
bowel function relies on absorption studies of D-xylose and 
tacrolimus and on the quantitation of fat in the stool. Most 
patients develop satisfactory absorption curves for D-xylose 
within the first postoperative month, and absorption con-
tinues to improve over time. Abnormal results obtained after 
1 month always should prompt an aggressive search for 
underlying pathology, especially rejection. The maintenance 
of satisfactory tacrolimus whole blood trough levels of 15 to 
20 nglmL on oral therapy alone is a good indicator of adequate 
absorption. In our patients, evidence of good absorptive 
function occurs at a mean of 28 days after transplantation 
and tends to be delayed longer in recipients of multivisceral 
grafts.33 The excretion of fat in the stool has been abnormal 
in almost all patients. However, clinical steatorrhea has not 
been a problem. 
Radiologic evaluations by standard barium gastrointestinal 
examination are valuable in assessing mucosal pattern and 
m?tility and are performed routinely after the first postoper-
ative week. A normal mucosal pattern is expected. Intestinal 
transit time is around 2 hours. Intestinal graft rejection, when 
mild, can be suspected when evidence of mucosal edema 
exists. Severe rejection, with exfoliation of the mucosa, ablates 
~he normal mucosal pattern and can be seen as segments of 
tubulized" intestine and strictures (Fig. 236-5). 
~MmifCAqflkp 
! ~efore a description of the variety of potential complications, 
'1 It is important to have a general perspective on the care of 
these patients. Comprehensive management of intestinal 
recipients requires a multidisciplinary approach by surgeons, 
anesthesiologists, nurses, critical care physicians, pathologists, 
~~d a host of internal medicine subspecialists. Easy access to 
lagnostic and therapeutic modalities, including mechanical 
=_;ucetue: 
FIGURE 236-5. Severely damaged allograft intestine in a recipient of a 
liver-small bowel after mUltiple episodes of rejection. Diffuse tubulized 
gut, strictures, and significant distention of the native duodenum are seen. 
ventilation, hemodialysis, bronchoscopy, gastrointestinal 
endoscopy, thromboelastography, percutaneous cholangiog-
raphy, ultrasonography, invasive and noninvasive contrast 
radiography, and sophisticated hemodynamic monitoring 
systems is paramount. 
More important than the above, however, is vigilance 
about patient care and attention to detail, on the part of both 
physicians and nurses. Problems in these patients can originate 
from a multiplicity of sources. Several assumptions can be 
made in these patients based on our experience: 
1. Preoperative deterioration of physical performance status 
predisposes to various organ system failures that persist 
in the postoperative period even though allograft function 
may be acceptable. 
2. Transplant cases are labor-intensive and patients require 
aggressive respiratory therapy, nutritional and antibiotic 
support, fluid management, and nursing care, often for 
prolonged periods in the intensive care unit. 
3. Immunotherapy doses in patients with multivisceral 
transplants tend to be higher than in patients with single 
organ transplants. 
4. The majority of patients develop episodes of infection 
and rejection after transplantation, often concomitantly. 
Any subjective complaints or objective abnormalities 
should be vigorously pursued until a cause is found or 
until the symptoms resolve. 
GRAFT REJECTION 
Intestinal allograft rejection can manifest as an array of 
symptoms that include fever, abdominal pain, distention, 
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nausea, vomiting, and a sudden increase in stomal output. 
The stoma may become edematous, erythematous, and 
friable. Gastrointestinal bleeding can occur in cases of severe 
uncontrollable rejection in which ulcerations and sloughing 
of the intestinal mucosa occur. Septic shock or acute respi-
ratory distress syndrome may develop. Bacterial or fungal 
translocation can occur during intestinal allograft rejection 
due to disruption of the intestinal mucosal barrier. Gut 
decontamination must be instituted during these episodes. 34 
Endoscopically, the transplanted intestinal mucosa loses 
its velvety appearance. It may become hyperemic or dusky as 
well as hypoperistaltic. Erythema may be focal or diffuse. 
The mucosa becomes friable, and diffuse ulcerations appear 
(Fig. 236-6). 
Histologically, there is variable presence of edema in the 
lamina propria and villous blunting. However, the presence 
of mononuclear cell infiltrates and cryptitis with apoptosis 
and regeneration are necessary for establishing the diagnosis 
of rejection. Neutrophils, eosinophils, and macro phages may 
be seen traversing the muscularis mucosa. 35,36 The degree of 
epithelial and crypt cell damage varies. Complete mucosal 
sloughing and crypt destruction are seen in grafts with 
A B 
FIGURE 236-6. (A) Normal endoscopic appearance of 
transplanted small intestine. (B) Moderate acute cellular 
rejection of an intestinal allograft demonstrating diffuse 
edema and focal erythema. 
severe rejection. The mucosal surface is partially replaced by 
inflammatory pseudomembranes and granulation tissue 
(Fig. 236-7). This may precipitate continuous blood loss as well 
as intermittent septic episodes from the damaged intestine. 
Chronic rejection has been observed in patients with 
persistent intractable rejection episodes. Clinically progressive 
weight loss, chronic diarrhea, intermittent fever, and gastroin-
testinal bleeding dominate the presentation. Histologically, 
villous blunting, focal ulcerations, epithelial metaplasia, and 
scant cellular infiltrate are present on endoscopic mucosal 
biopsy specimens. Full-thickness intestinal biopsies show 
obliterative thickening of intestinal arterioles. 
Historically, the incidence of acute intestinal allograft 
rejection during the first 90 days after transplantation was 
92% in isolated small bowel recipients and 66% in recipients 
of composite grafts, suggesting that the liver is "protective" 
for the intestine, as is seen experimentally.37,38 Interestingly, 
the incidence of acute liver allograft rejection in recipients of 
composite grafts is 43%, which is similar to that seen after 
isolated liver transplantation.30 However, the rate of acute 
rejection has steadily decreased to current levels of approxi-
mately 30% with the use of a preconditioning protocol. 
c 
FIGURE 236-7. Acute cellular rejection. (A) Endoscopic biopsy sample obtained 14 days after transplantation showed widening of the lamina propria 
with increased mononuclear celis, which were often cuffed around small vessels and infiltrating the crypt epithelium (arrow; hematoxylin and eosin, 
original magnification x140). (B)The reaction was more intense in biopsies that contained lymphoid nodules and where blastogenesis, focal 
ulcerations, congestion, and neutrophil plugging of capillaries were also seen (moderate acute cellular rejection; hematoxylin and eosin, original 
magnification x140). (C) Uncontrolled acute rejection eventually resulted in widespread mucosal destruction; the mucosa was replaced by 
granulation tissue. Note the overlying inflammatory pseudomembrane (arrow; hematoxylin and eosin, original magnification x3S0). 
, 
Lower overall immunosuppression has subsequently allowed 
a concomitant reduction in Epstein-Barr virus and cyto-
megalovirus disease, especially in pediatric recipients. 
Mild graft rejection is treated initially with intravenous 
methylprednisolone, and with a methylprednisolone taper 
in cases of moderate rejection. The tacrolimus trough levels 
in whole blood should reach 15 to 25 ng/mL, with the drug 
administered by either the oral or the intravenous route. 
OKT3 is used when rejection has progressed with a steroid 
taper; however, it should be entertained as the initial thera-
peutic agent in cases of severe mucosal injury and crypt 
damage. The use of cyclophosphamide/mycophenolate 
mofetil induction therapy or bone marrow augmentation 
had no beneficial effect on the frequency of rejection.3o•36 
POSTOPERATIVE HEMORRHAGE 
Coagulopathy is more often an intraoperative problem that 
relates to liver dysfunction, qualitative and quantitative 
platelet defects, and fibrinolysis. 38 Intraoperative bleeding is 
further promoted by vascularized adhesions due to previous 
surgery and portal hypertension. Temporary graft reperfusion 
coagulopathy mediated by plasminogen activators from the 
graft may occur. 39 Efforts are made to normalize these global 
aspects of coagulation by the end of the operative procedure 
so that in the absence of liver dysfunction, the coagulopathy 
is usually minor in the postoperative period. Postoperative 
intra-abdominal bleeding is most often a technical problem, 
arising from vascular anastomoses or extensive, raw peritoneal 
surfaces. Certainly, coagulation parameters should be normal-
ized, if postoperative bleeding occurs; if bleeding is proved, 
the origin should be presumed to be surgical and managed 
as such by early reexploration. 
BILIARY COMPLICATIONS 
Continuity of the biliary axis is surgically re-established in 
~~ltivisceral grafts. Correspondingly, these grafts can develop 
bihary system-related surgical complications (i.e., leaks and 
obstructions ). 
Biliary leaks usually occur within the first 2 weeks after 
transplantation and may herald their presence with bilious 
d~ainage from the abdominal wound or drains or merely 
With unexplained sepsis. The response to external bilious 
drainage should be immediate exploration with surgical 
revision of the biliary dehiscence. In the case of unexplained 
sepsis in any intestinal transplant recipient, all surgical anas-
tomoses should be radiographically inspected (with percuta-
neous cholangiography), and if leakage is suspected, they 
should be revised. There is no place for percutaneous diversion 
of biliary or intestinal leakage in these patients, since both 
Wound healing and antimicrobial immunity are impaired by 
rnultimodal immunotherapy. 
k .Biliary obstruction generally follows an anastomotic 
i stncture and is a delayed complication, but any clinical pic-
r ~ure that resembles cholangitis or biliary obstruction should 
b~ .followed with cholangiography to prove patency of the 
ihary tree, regardless of the timing after transplantation. 
VASCULAR COMPLICATIONS 
~ajor arterial thrombosis is a disastrous complication that 
eads to massive necrosis of the organs correspondingly 
supplied. Elevation of hepatic enzymes and pallor of the 
intestinal stoma are accompanied by clinical deterioration, 
fulminant sepsis, and hepatic coma. Isolated small bowel 
grafts can be removed with the expectation of patient recovery, 
but in patients with composite grafts, the event is usually 
fatal unless early retransplantation can be performed. Patency 
of the arteries can be rapidly confirmed with Doppler 
ultrasonographic examination. 
Since the superior mesenteric vein-portal vein axis is pre-
served in the composite grafts, venous outflow thrombosis 
is less likely to occur in these recipients. Isolated small bowel 
grafts have an anastomosis of these veins that can occlude. 
Ascites, stomal congestion, and mesenteric infarction are the 
ultimate result. 
Neither of these problems is associated with subtle clinical 
signs; diagnosis should be prompt and obvious. In our series, 
isolated thrombosis of the hepatic artery has occurred in a 
pediatric recipient of a liver-small bowel graft, with conse-
quent hepatic gangrene. This patient required retransplanta-
tion of the liver component of the graft, even though a full 
liver-small bowel graft was desirable. 
Incomplete obstruction of major inflow or outflow vessels 
may be suspected on biopsy or based on clinical and laboratory 
evidence of organ dysfunction. Contrast vascular radiographic 
studies are confirmatory, and the correction is surgical or, in 
some cases, with balloon dilatation. 
GASTROINTESTINAL COMPLICATIONS 
Gastrointestinal bleeding after intestinal transplantation is 
an ominous sign that requires prompt attention. Rejection 
or infection are the most probable causes and should be 
immediately diagnosed or ruled out on the basis of entero-
scopic biopsy results. The diagnosis of rejection relies not 
only on histologic evidence but also on the endoscopic 
appearance of the mucosa (Figs. 236-6 and 236-7). Bleeding 
from ulcerated Epstein-Barr virus- or cytomegalovirus-
induced lesions can be easily differentiated by gross endoscopic 
examination. Empiric therapy for rejection is not acceptable. 
Leakage of either the proximal or the distal gastrointestinal 
anastomosis can occur in any recipient, but it is more 
common in pediatric patients than in adults. Any fresh 
surgical margin, including the native duodenal and colonic 
stumps and gastrostomy sites, are vulnerable to poor wound 
healing and subsequent leakage. Presentation is often dramatic 
(florid sepsis), and confirmation is with radiologic contrast 
imaging. Surg revision, evacuation of peritoneal soilage, 
and often reexploration are required to eliminate the 
contamination effectively. Again, sepsis without an obvious 
source should prompt the performance of contrast studies 
to document the integrity of all gastrointestinal anastomoses; 
if the findings are inconclusive, diagnostic laparotomy is 
indicated. 
Atony of the native stomach and pylorospasm that pro-
duce early satiety or vomiting are common and self-limiting. 
The evolution of motility patterns in the denervated 
allograft intestine is not fully understood. Hypermotility of 
the allograft intestine occurs early after transplantation; in 
the absence of rejection or bacterial overgrowth, it can be 
controlled with agents such as paregoric, loperamide, or 
pectin. Sudden changes in intestinal motility, particularly 
when accompanied by abdominal distention and vomiting 
in the case of decreased motility, should initiate a search for 
rejection. 
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INFECTIONS 
Historically, frequency of infectious complications has been 
high and was responsible for the significant morbidity and 
mortality initially reported after intestinal transplantation. 
The high incidence of serious infectious complications was 
due in part to the relatively high level of immunosuppression 
required to maintain the graft in these intestinal recipients. 
Other predisposing factors include the severity of the preop-
erative liver failure as well as the presence of intra-abdominal, 
pulmonary, or intravenous line-induced sepsis before trans-
plantation. Also, technically more difficult transplantation 
procedures with increased operative time, transfusion require-
ments, and likelihood of reexploration reflect the advanced 
disease of these patients. Recipients of small bowel grafts 
have the lowest incidence of complications because of the 
more elective nature of their operations. 
Although current immunosuppressive modifications 
have decreased the incidence of life-threatening septic com-
plications, the recognition and management of infection is 
still an important component of the care of these patients. 
Infectious pathogens include bacteria, fungi, and viruses. 
Infections are related (in order of frequency) to intravenous 
lines, the abdominal wound, deep abdominal abscesses, 
peritonitis, and pneumonia. Bacterial translocation in grafts 
damaged by rejection illustrates the need for concomitant 
antirejection and antimicrobial therapy and is a frequent 
source of infection. 
Of the bacterial pathogens, staphylococcal and enterococcal 
species are common, whereas gram-negative rods usually 
accompany polymicrobial infections. Not uncommonly, 
separate sources of infection occur simultaneously, or mixed 
infections from the same source are present. This leads 
to multiple antibiotic regimens and sets the stage for the 
development of resistant organisms. Panresistant enterococcal 
isolates are an increasing problem. Persistence of a physiologic 
hyperdynamic state in a patient being treated for proven 
infection should raise the suspicion of retained phlegmonous 
material in the abdomen or the possibility of rejection.40.4! 
Fungal infections become problematic after heavy treat-
ment for rejection, massive antibiotic usage, intestinal leaks, 
and multiple surgical explorations. The authors routinely 
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TABLE 236-3. PEDIATRIC INTESTINAL 
TRANSPLANTATION: CYTOMEGALOVIRUS 
DISEASE BY ERA 
Year 
1990-1995 
1995-1997 
1997-1998 
1998-2001 
2002-2003 
Drug Rate, 0/0 
Tacrolimus/steroids 23 
Cyclophosphamide 56 
Tacrolimus/steroids 11 
Daclizumab 4 
Thymoglobulin preconditioning protocol 5 
employ low-dose amphotericin B prophylaxis in patients 
with these complications. Established fungal infections 
require long-term, full-dose antibiotic therapy and reduction 
of immunotherapy. All persistently septic recipients are 
potential candidates for moderation of immunosuppressant 
dosages, if no coexistent cellular rejection is present. However, 
complete withdrawal of immunosuppression has been impos-
sible in this recipient population owing to a high incidence of 
rebound rejection, which then mandates augmentation of 
immunotherapy. 
Historically, clinical cytomegalovirus infection has 
occurred in 36% of intestinal graft recipients and often 
involves the allograft intestine. The current incidence of 
cytomegalovirus disease is approximately 5% (Table 236-3). 
Although the incidence and distribution of disease according 
to donor and recipient cytomegalovirus serologic status is 
similar in adults (44%) and children (31 %), the clinical 
course is dramatically better in children. Successful clinical 
management has been accomplished in 88% of episodes 
using ganciclovir alone or ganciclovir in combination with 
cytomegalovirus-specific hyperimmunoglobulin. Immuno-
suppression is maintained at baseline and reduced only in 
the face of deteriorating clinical disease, thus decreasing the 
risk of rebound rejection.29 A cytomegalovirus-positive 
donor graft transplanted into a cytomegalovirus-negative 
recipient is a significant risk factor for cytomegalovirus 
disease, but monitoring for pp65 antigenemia and preemp-
tive therapy allow the successful use of cytomegalovirus-
mismatched organs. Clinical presentation is generally 
enteritis of variable severity with focal ulcerations and 
bleeding (Fig. 236-8). 
FIGURE 236-8. (A) Endoscopic appearance of cytomegaloviral enteritis is characterized by hyperemic erosions. (8) The diagnosis was confirmed 
histologically by the presence of characteristic inclusions, by staining for viral antigens, or both. Note the focal neutrophilic inflammation 
(immunoperoxidase for cytomegalovirus antigens, original magnification x350). 
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TABLE 236-4. PEDIATRIC INTESTINAL 
TRANSPLANTATION: PTLD BY ERA 
Year 
1990-1995 
1995-1997 
1997-1998 
1998-2001 
2002-2003 
Drug Rate, % 
Tacrolimus/steroids 44 
Cyclophosphamide 19 
Tacrolimus/steroids 33 
Daclizumab 17 
Thymoglobulin preconditioning protocol 5 
Less commonly, respiratory syncytial virus, adenovirus, 
and parainfluenza virus infections occur in the pediatric 
population. All viral infections are opportun~stic and have as 
a common denominator the need for aggressive treatment of 
rejection episodes in complicated patients with high Acute 
Physiologic and Chronic Health Evaluation (APACHE) 
scores. 
Post-transplantation lymphoproliferative disease associated 
with Epstein-Barr virus occurs in 20% of patients, and 
children (27%) have traditionally been at a significantly 
higher risk than adults (11 %). Presentation varies from 
totally asymptomatic observations at routine endoscopy to 
nonspecific intestinal and systemic symptoms to bleeding, 
lymphadenopathy, and tumors to fulminant disease. Risk 
factors other than age include the type of graft, splenectomy, 
and the use of OKT3. Therapy includes the reduction and 
withdrawal of immunosuppression, antiviral therapy using 
ganciclovir, acyclovir, and/or hyperimmunoglobulin, ritux-
imab (anti-CD 20 monoclonal antibody), and chemother-
apy. Rebound rejection is a. significant co~tributorK to 
mortality.31,37,42 With current ImmunosuppreSSIVe practICe, 
the post-transplant lymphoproliferative disease rate has 
decreased to less than 10% (Table 236-4). 
GRAFT-VERSUS-HOST DISEASE 
Skin changes consistent with graft -versus-host disease 
were diagnosed by histopathologic criteria and confirmed 
FIGURE 236-9. Patient and graft survival. (From 
Abu-Elmagd K, Reyes J, Bond G, et al: Clinical 
intestinal transplantation: A decade of experience 
at a single center. Ann Surg 2001 ;234:404-417.) 
by immunohistochemical studies visualizing donor cell 
infiltration into the lesions on two occasions or by flow 
cytometry detecting elevated donor cell chimerism in 
peripheral blood. One child died with hereditary IgG an.d 
IgM deficiency,43 and one adult developed a complex chrOnIC 
graft-versus-host disease in association with post-transplant 
lymphoproliferative disease. All other cases have been 
treated with optimization of immunosuppression and 
limited steroid therapy, if necessary. 
PRESENT STATUS AND FUTURE 
The causes of graft and patient loss are invariably multifac-
torial and complex. The evolution of technical and clinical 
management factors have improved outcome (Fig. 236-9). 
However, the interplay between the need for high levels of 
immunosuppression, the high incidence of rejection, and 
the opportunistic infections consequent to this remain the 
major stumbling block to further progress. 
Accumulated experience has allowed the development of 
clinical and surgical strategies that benefit a very complex 
group of patients. Reserved optimism is taken in light of 
previous experience with intestinal transplantation, as 
well as the grim outcome for patients not transplanted. 
Nonetheless, the overall actuarial survival rate at 1 and 5 years 
is 72% and 48%, respectively, and full nutritional support has 
been achieved in 91 % of surviving patients (see Fig. 236-5). 
Improved results have been achieved in the pediatric popu-
lation between 2 and 18 years of age (65% at 5 years),37 
The transplantation of the isolated intestinal graft provides 
better patient survival at all follow-up times (see Fig. 236-6). 
However, because of the higher incidence of rejection with 
this type of graft, the long-term outcome of all types of 
grafts (isolated intestine or composite grafts) is similar 
(Fig. 236-10) and is estimated to be about 50% at 5 years.31 ,37 
Improved strategies for immunosuppression have low-
ered the morbidity rate of transplantation and the concur-
rent infection rate and may allow for improved survival in 
the current era of preconditioning with Thymoglobulin. 
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Under the best of circumstances, the outlay of financial 
and time expenditures in composite and isolated small bowel 
transplant recipients is impressive. For best possible results, 
candidates who are nutritionally optimal and free of 
active infection should be selected. Donor organs should be 
discarded if they are less than perfect. Even with technically 
perfect operations, the managing physicians should expect a 
host of postoperative difficulties and be prepared to support 
these patients fully for an indefinite period of time. 
Managing the balance between excessive and inadequate 
immunosuppression in the face of potentially virulent infec-
tions, the pursuit of rejection and sources of infection, and 
maintenance of comprehensive critical care support are the 
most challenging tasks. 
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